Glutaminergic Transmission in Autism : Molecular Imaging Exploration

• Status: Completed
• Trial end date: 2019-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Tours

Criteria

Inclusion Criteria:

• Male

• Between 18 years-old and 45 years-old

• Informed, written consent obtained from patient or his representant

• Subject with an affiliation to French social security

• For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS)

• For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1

Exclusion Criteria:

• Contraindications to MRI

• Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months

• Any unstable or uncontrolled disease, clinically significant

• Participation to an other experimental protocol with drug or irradiant exam

• Person under exclusion period because of previous participation to an other experimental protocol

• Person under temporary guardianship

• Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly

• For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSM-IV)